novo nordisk ozempic - Search News

Novo Nordisk's next-gen obesity drug Cagrisema

Hosted on MSN · 11h

Novo Nordisk Expects Positive News on Weight-Loss Drugs, Soon, From FDA

The drugmaker expects the regulator to remove Wegovy and Ozempic from its shortage list, blocking other companies from legally selling cheap knockoff versions.

The New York Times · 11h

Novo Nordisk Annual Sales Jump on Higher Demand for Obesity Drugs

The Danish maker of Ozempic and Wegovy reported a 25 percent increase in sales to $40.6 billion, but said it expected slower growth this year.

Fortune on MSN · 14h

As growth slows, CFO says Novo Nordisk is prepping for the next generation of weight loss drugs

Novo’s newest GLP-1, CagriSema, is the first big test of Novo Nordisk’s future as the leader in the obesity treatment market. The drug is more potent than Ozempic and Wegovy, expanding treatment to heavier patients while perhaps reducing treatment times for other individuals.

Novo Nordisk's stock rises

The Motley Fool on MSN · 8h

Why Novo Nordisk Stock Is Soaring Today

Shares of Novo Nordisk ( NVO 4.37%) were moving higher on Wednesday. The company's stock gained 4.9% as of 1:50 p.m. ET, but gained as much as 5.8% earlier in the day. The leg up comes as the S&P 500 ( ^GSPC 0.26%) gained 0.2%, and the Nasdaq Composite ( ^IXIC 0.02%) lost 0.1% on the day.

Wall Street Journal · 15h

Novo Nordisk Earnings Boost Stock in Ozempic Maker

Novo Nordisk stock gained, lifted by strong sales growth and guidance from the maker of Wegovy and Ozempic. Shares in Novo, one of Europe's largest listed companies, advanced nearly 3% in Denmark. Dig

SchaeffersResearch.com · 11h

Novo Nordisk Stock Pops on Upbeat Earnings

Pharmaceutical concern Novo Nordisk A/S (NYSE:NVO) is up 4.9% at $86.63 at last glance. The company posted strong fourth-quarter results and better-than-expected full-year revenue for 2024, as weight-loss drugs Wegovy and Ozempic reeled in billions,

5h

Novo Nordisk’s (NVO) CEO Is Not Worried About Government Price Negotiations

Novo Nordisk (NVO), a pharmaceutical company, isn’t too worried about the U.S. government’s plan to negotiate prices for its ...

18hon MSN

Novo Nordisk sales beat estimates, but the story wasn’t Ozempic

Danish drugmaker Novo Nordisk on Wednesday posted another quarter of rapid profit growth, though the story for once wasn’t ...

14h

Novo Nordisk Jumps After Ozempic Decidedly Beats. But 'Periodic Supply Constraints' Expected.

Novo Nordisk stock jumped Wednesday on better-than-expected fourth-quarter sales, helped by an Ozempic beat.

4hon MSN

Novo Nordisk missed its diversity targets last year, and its CEO paid a financial price

Novo Nordisk's CEO took a $1.5 million pay cut in 2024 as the pharma giant's share price tanked and it missed profit and DEI ...

13h

Novo Nordisk Q4 Earnings: Outperformance Suggests Stock Price Comeback Starts Today

Novo Nordisk today announced 2024 earnings, reporting a 26% increase in annual sales to ~$40.56bn. Read why I upgrade NVO ...

8don MSN

Novo Nordisk’s Ozempic Gets FDA Approval as Kidney-Disease Treatment

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type ...

1d

Will This New GLP-1 Drug be More Powerful Than Ozempic?

CagriSema combines semaglutide, the active ingredient in Wegovy, with a molecule that mimics a pancreatic hormone.

Some results have been hidden because they may be inaccessible to you

Show inaccessible results